Literature DB >> 30251071

Nonsteroidal Anti-inflammatory Drugs for Endoscopic Retrograde Cholangiopancreatography Postoperative Pancreatitis Prevention: a Systematic Review and Meta-analysis.

Lan Liu1, Chenghao Li2, Yuan Huang2, Haiyan Jin3.   

Abstract

BACKGROUND OR
PURPOSE: There is controversy regarding the efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) for prophylaxis against endoscopic retrograde cholangiopancreatography (ERCP) postoperative pancreatitis. Therefore, we conducted a systematic review and meta-analysis to evaluate the efficacy of NSAIDs for prophylaxis against post-ERCP pancreatitis (PEP).
METHODS: PubMed, EMBASE, and Cochrane library databases were searched for relevant randomized controlled trials (RCTs). Selected RCTs were pooled under a fixed effects model to generate the relative risks (RRs) and their corresponding 95% confidence intervals (CIs).
RESULTS: Nineteen RCTs involving a total of 5031 patients (2555 in the intervention group and 2476 in the control group) were selected. Overall, NSAIDs were associated with a significant reduction in risk of PEP (RR = 0.54, 95% CI 0.45 to 0.64, I2 = 40.4%) and moderate to severe PEP (RR = 0.45, 95% CI 0.30 to 0.67, I2 = 0%) compared with the control group. Subgroup analyses were performed according to route of administration (rectal or other), type of NSAIDs (diclofenac, indomethacin, or other), timing of administration (pre-ERCP, post-ERCP, or other), and patient population (high risk or general). Subgroup analyses showed difference in clinical efficacy of NSAID prophylaxis regardless of route, timing, or specific type of NSAID.
CONCLUSION: NSAIDs were associated with a significant reduction in risk of PEP and moderate to severe PEP compared to the control group.

Entities:  

Keywords:  Endoscopic retrograde cholangiopancreatography; Meta-analysis; Nonsteroidal anti-inflammatory drugs; Pancreatitis; Randomized controlled trials; Systematic review

Year:  2018        PMID: 30251071     DOI: 10.1007/s11605-018-3967-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  40 in total

1.  Complications of diagnostic and therapeutic ERCP: a prospective multicenter study.

Authors:  E Masci; G Toti; A Mariani; S Curioni; A Lomazzi; M Dinelli; G Minoli; C Crosta; U Comin; A Fertitta; A Prada; G R Passoni; P A Testoni
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

2.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

3.  Rectal nonsteroidal anti-inflammatory drugs administration is effective for the prevention of post-ERCP pancreatitis: An updated meta-analysis of randomized controlled trials.

Authors:  Chong Yang; Yanting Zhao; Wentao Li; Shikai Zhu; Hongji Yang; Yu Zhang; Xi Liu; Nan Peng; Ping Fan; Xin Jin
Journal:  Pancreatology       Date:  2017-07-17       Impact factor: 3.996

4.  Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy: the EPISOD randomized clinical trial.

Authors:  Peter B Cotton; Valerie Durkalski; Joseph Romagnuolo; Qi Pauls; Evan Fogel; Paul Tarnasky; Giuseppe Aliperti; Martin Freeman; Richard Kozarek; Priya Jamidar; Mel Wilcox; Jose Serrano; Olga Brawman-Mintzer; Grace Elta; Patrick Mauldin; Andre Thornhill; Robert Hawes; April Wood-Williams; Kyle Orrell; Douglas Drossman; Patricia Robuck
Journal:  JAMA       Date:  2014-05       Impact factor: 56.272

5.  Is rectal indomethacin effective in preventing of post-endoscopic retrograde cholangiopancreatography pancreatitis?

Authors:  Zoltán Döbrönte; Zoltán Szepes; Ferenc Izbéki; Judit Gervain; László Lakatos; Gyula Pécsi; Miklós Ihász; Lilla Lakner; Erzsébet Toldy; László Czakó
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

6.  Prophylaxis of post-ERCP pancreatitis: a practice survey.

Authors:  Jean-Marc Dumonceau; Johanne Rigaux; Michel Kahaleh; Carlos Macias Gomez; Alain Vandermeeren; Jacques Devière
Journal:  Gastrointest Endosc       Date:  2010-03-11       Impact factor: 9.427

7.  Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP.

Authors:  Rasoul Sotoudehmanesh; Morteza Khatibian; Shadi Kolahdoozan; Sanaz Ainechi; Ramin Malboosbaf; Mehdi Nouraie
Journal:  Am J Gastroenterol       Date:  2007-03-13       Impact factor: 10.864

8.  Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction.

Authors:  P R Tarnasky; Y Y Palesch; J T Cunningham; P D Mauldin; P B Cotton; R H Hawes
Journal:  Gastroenterology       Date:  1998-12       Impact factor: 22.682

9.  Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial.

Authors:  Víctor Fernando Andrade-Dávila; Mariana Chávez-Tostado; Carlos Dávalos-Cobián; Jesús García-Correa; Alejandro Montaño-Loza; Clotilde Fuentes-Orozco; Michel Dassaejv Macías-Amezcua; Jesús García-Rentería; Jorge Rendón-Félix; José Antonio Cortés-Lares; Gabriela Ambriz-González; Ana Olivia Cortés-Flores; Andrea del Socorro Alvarez-Villaseñor; Alejandro González-Ojeda
Journal:  BMC Gastroenterol       Date:  2015-07-21       Impact factor: 3.067

10.  Intravenous injection of low-dose flurbiprofen axetil for preventing post-ERCP pancreatitis in high-risk patients: An interim analysis of the trial.

Authors:  Yuji Fujita; Sho Hasegawa; Yuri Kato; Ken Ishii; Akito Iwasaki; Takamitsu Sato; Yusuke Sekino; Kunihiro Hosono; Atsushi Nakajima; Kensuke Kubota
Journal:  Endosc Int Open       Date:  2016-09-21
View more
  3 in total

1.  Optimal timing of rectal diclofenac in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.

Authors:  Christina J Sperna Weiland; Xavier J N M Smeets; Robert C Verdonk; Alexander C Poen; Abha Bhalla; Niels G Venneman; Wietske Kievit; Hester C Timmerhuis; Devica S Umans; Jeanin E van Hooft; Marc G Besselink; Hjalmar C van Santvoort; Paul Fockens; Marco J Bruno; Joost P H Drenth; Erwin J M van Geenen
Journal:  Endosc Int Open       Date:  2022-03-14

2.  Post-ERCP Pancreatitis: Risk factors and role of NSAIDs in primary prophylaxis.

Authors:  Muhammad Haseeb Nawaz; Shahid Sarwar; Muhammad Arif Nadeem
Journal:  Pak J Med Sci       Date:  2020 Mar-Apr       Impact factor: 1.088

3.  Rectal nonsteroidal anti-inflammatory drugs and pancreatic stents in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: A network meta-analysis.

Authors:  Yin Shou-Xin; Han Shuai; Kong Fan-Guo; Dao Xing-Yuan; Huang Jia-Guo; Peng Tao; Qi Lin; Shang Yan-Sheng; Yang Ting-Ting; Zhao Jing; Li Fang; Qi Hao-Liang; Liu Man
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.